Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis
- PMID: 27701407
- PMCID: PMC5315542
- DOI: 10.1038/tp.2016.159
Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis
Abstract
Psychotic disorders affect ~3% of the general population and are among the most severe forms of mental diseases. In early stages of psychosis, clinical aspects may be difficult to distinguish from one another. Undifferentiated psychopathology at the first-episode of psychosis (FEP) highlights the need for biomarkers that can improve and refine differential diagnosis. We investigated gene expression differences between patients with FEP-schizophrenia spectrum (SCZ; N=53) or FEP-Mania (BD; N=16) and healthy controls (N=73). We also verified whether gene expression was correlated to severity of psychotic, manic, depressive symptoms and/or functional impairment. All participants were antipsychotic-naive. After the psychiatric interview, blood samples were collected and the expression of 12 psychotic-disorder-related genes was evaluated by quantitative PCR. AKT1 and DICER1 expression levels were higher in BD patients compared with that in SCZ patients and healthy controls, suggesting that expression of these genes is associated more specifically to manic features. Furthermore, MBP and NDEL1 expression levels were higher in SCZ and BD patients than in healthy controls, indicating that these genes are psychosis related (independent of diagnosis). No correlation was found between gene expression and severity of symptoms or functional impairment. Our findings suggest that genes related to neurodevelopment are altered in psychotic disorders, and some might support the differential diagnosis between schizophrenia and bipolar disorder, with a potential impact on the treatment of these disorders.
Conflict of interest statement
CN has received a scholarship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and has served as a consultant or advisory board member for Janssen. AG was on the speakers' bureau and/or has acted as a consultant for Janssen-Cilag in the last 12 months and has also received research support from Brazilian government institutions (CNPq). EB has been supported by CNPq, CAPES and FAPESP. RAB has received research funding from FAPESP, CNPq, CAPES, Fundação Safra, Fundação ABADS, Janssen, Eli Lilly, Lundbeck, Novartis and Roche, has served as a speaker for Astra Zeneca, Bristol, Janssen, Lundbeck and Revista Brasileira de Psiquiatria and is a shareholder of Radiopharmacus Ltda and Biomolecular Technology. The remaining authors declare no conflict of interest.
References
-
- Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64: 19–28. - PubMed
-
- Bogren M, Mattisson C, Isberg PE, Nettelbladt P. How common are psychotic and bipolar disorders? A 50-year follow-up of the Lundby population. Nord J Psychiatry 2009; 63: 336–346. - PubMed
-
- Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998; 172: 53–59. - PubMed
-
- Fuste M, Pinacho R, Melendez-Perez I, Villalmanzo N, Villalta-Gil V, Haro JM et al. Reduced expression of SP1 and SP4 transcription factors in peripheral blood mononuclear cells in first-episode psychosis. J Psychiatr Res 2013; 47: 1608–1614. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
